Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases.

Abstract

Lamivudine, adefovir, telbivudine, and entecavir are nucleoside analogues that can inhibit hepatitis B virus replication and are licensed in China by the Food and Drug Administration. This study presents the cases of 2 patients who were chronically infected with HBV and suffered hepatic failure resulting from withdrawal of telbivudine and adefovir, respectively.

• Authors: Junshuai Wang, Minxin Wang, Yuancheng Huang
• Journal: Scandinavian journal of infectious diseases (Scand J Infect Dis) Vol. 45 Issue 2 Pg. 158-60 (Feb 2013) ISSN: 1651-1980 [Electronic] England
• PMID: 22830672 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antiviral Agents
• Organophosphonates
• Telbivudine
• Lamivudine
• entecavir
• Guanine
• adefovir
• Adenine
• Thymidine

Topics

• Adenine (adverse effects, analogs & derivatives, therapeutic use)
• Adult
• Antiviral Agents (adverse effects, therapeutic use)
• Guanine (adverse effects, analogs & derivatives, therapeutic use)
• Hepatitis B, Chronic (drug therapy, pathology)
• Histocytochemistry
• Humans
• Lamivudine (adverse effects, therapeutic use)
• Liver Failure, Acute (etiology, pathology, virology)
• Liver Transplantation
• Male
• Medication Adherence
• Necrosis
• Organophosphonates (adverse effects, therapeutic use)
• Telbivudine
• Thymidine (adverse effects, analogs & derivatives, therapeutic use)